A systematic UHPLC-Q-TOF-MS/MS-based strategy for analysis of chemical constituents and related in vivo metabolites of Buyang Huanwu decoction
- PMID: 39447712
- DOI: 10.1016/j.jep.2024.118987
A systematic UHPLC-Q-TOF-MS/MS-based strategy for analysis of chemical constituents and related in vivo metabolites of Buyang Huanwu decoction
Abstract
Ethnopharmacological relevance: Buyang Huanwu Decoction (BYHWD), a traditional Chinese medicine, is one of the classic prescriptions for the treatment of ischemic stroke in clinical practice. It has the effects of tonifying qi, activating blood circulation, and promoting meridian circulation. However, its chemical analysis has not been clarified, which greatly hinders its further clinical application. Therefore, it is necessary to clarify the chemical constituents and metabolites profile of BYHWD in vivo.
Aim of the study: Characterizing the chemical basis of BYHWD in vitro, and combing studies of related metabolism in vivo to screen out the potential active components of BYHWD with pharmacological effects in vivo.
Materials and methods: Twelve male rats weighed 200 ± 20 each were selected for the experiments. According to the fragmentation of different structural types of components and diagnostic ions, UHPLC-Q-TOF-MS/MS was used to classify and clarify the unknown components of BYHWD and identify the material basis of BYHWD in vitro. Then, rat plasma, tissues, feces, and urine were collected for analysis. Based on the similarity of MS responses (accurate molecular weight and secondary fragmentation) and chromatographic behavior (retention time), the in vivo prototype and metabolites were analyzed. Through the phase I and phase II metabolism law, a metabolite library was established to analyze the prototype-matched metabolites.
Results: A total of 121 in vitro compounds and 55 in vivo prototypes of BYHWD were identified, corresponding to 123 matched prototypes. It was mainly composed of flavonoids, triterpene saponins, nucleosides and lactones both in vitro and in vivo. Quercetin, ligustilide, astragaloside IV, calycosin, paeoniflorin and ferulic acid were the main prototypes and metabolites in plasma and urine.
Conclusion: Quercetin, ligustilide, astragaloside IV, calycosin, paeoniflorin and ferulic acid were the main active ingredients of BYHWD.
Keywords: Buyang huanwu decoction; Chemical constituents and metabolites analysis; Pharmacological substance basis; UHPLC-Q-TOF-MS/MS.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Buyang Huanwu Decoction ameliorates ischemic stroke by modulating multiple targets with multiple components: In vitro evidences.Chin J Nat Med. 2018 Mar;16(3):194-202. doi: 10.1016/S1875-5364(18)30047-5. Chin J Nat Med. 2018. PMID: 29576055
-
[Metabolomic study on urine of chronic inflammation rats treated with Buyang Huanwu Decoction based on UPLC-Q-TOF-MS].Zhongguo Zhong Yao Za Zhi. 2023 Oct;48(19):5345-5355. doi: 10.19540/j.cnki.cjcmm.20230510.401. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 38114124 Chinese.
-
The integrated study on the chemical profiling and in vivo course to explore the bioactive constituents and potential targets of Chinese classical formula Qingxin Lianzi Yin Decoction by UHPLC-MS and network pharmacology approaches.J Ethnopharmacol. 2021 May 23;272:113917. doi: 10.1016/j.jep.2021.113917. Epub 2021 Feb 17. J Ethnopharmacol. 2021. PMID: 33609729
-
Rapid characterization and identification of the chemical constituents and the metabolites of Du-zhi pill using UHPLC coupled with quadrupole time-of-flight mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Oct 15;1209:123433. doi: 10.1016/j.jchromb.2022.123433. Epub 2022 Aug 23. J Chromatogr B Analyt Technol Biomed Life Sci. 2022. PMID: 36055062 Review.
-
Systematic evaluation and re-evaluation of buyang huanwu decoction in treating ischemic stroke.Complement Ther Med. 2022 Nov;70:102860. doi: 10.1016/j.ctim.2022.102860. Epub 2022 Jul 19. Complement Ther Med. 2022. PMID: 35868491
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials